Presenting Company & Sponsor News
Inovio Pharmaceuticals and Academic Collaborators Receive $16 Million HIV Grant From National Institute of Allergy and Infectious Diseases
March 16, 2015 – Inovio Pharmaceuticals, Inc. (Nasdaq:INO) announced today that the company and its academic collaborators, including the University of Pennsylvania (UPenn), were awarded a new five-year $16 million Integrated Preclinical/Clinical AIDS Vaccine Development Program grant from the National Institute of Allergy and Infectious Diseases (NIAID).
NeoStem Announces PreSERVE AMI Clinical Trial One-Year Follow-Up Results
March 16, 2015 – NeoStem, Inc. (NASDAQ:NBS), a biopharmaceutical company developing novel cell based personalized medicine therapies, announced today presentation of updated efficacy and safety results from the one-year follow-up for its Phase 2 PreSERVE study and additional analyses of certain functional tests at ACC.15, the American College of Cardiology’s 64th Annual Scientific Session and Expo, in San Diego, California.
TiGenix Completes Treatment in Phase I Sepsis Challenge Trial with Cx611
March 12, 2015 – TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived stem cells, or eASCs, in inflammatory and autoimmune diseases, announced today that it has completed the treatment of 32 subjects in its Phase I trial of Cx611 in a sepsis challenge model. No serious adverse events have been reported. Full results will be announced in the second quarter of 2015.
Capricor Therapeutics Announces Uplisting to NASDAQ Capital Market
March 5, 2015 – Capricor Therapeutics, Inc. (OTCQB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that it has been approved to begin trading its common stock on the NASDAQ Capital Market. Capricor’s common stock will begin trading under the same symbol, CAPR, at the opening of market hours on Monday, March 9, 2015.
Asterias Biotherapeutics Initiates Patient Enrollment for Phase 1/2a Clinical Trial of AST-OPC1 in Newly Injured People with Complete Cervical Spinal Cord Injury
March 5, 2015 – Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, announced today that Atlanta-based Shepherd Center, one of the nation’s top rehabilitation hospitals for spinal cord injury and brain injury, has commenced enrollment for the Phase 1/2a clinical trial of AST-OPC1 (oligodendrocyte progenitor cells) in newly injured patients with sensory and motor complete cervical spinal cord injury (SCI).
Pluristem and Hadassah Medical Center Announce Significant Data Showing PLX-R18 Cells Improve Bone Marrow Transplantation
March 3, 2015 – Pluristem Therapeutics Inc. (NasdaqCM: PSTI) TASE: PSTI),a leading developer of placenta-based cell therapy products, announced today strong positive data from a preclinical study of PLX-R18 cells to improve outcomes of bone marrow transplantation. In the study, conducted in conjunction with Hadassah Medical Center’s Department of Bone Marrow Transplantation and Cancer Immunotherapy, mice with damaged bone marrow who received intramuscular injections of PLX-R18 cells together with a bone marrow transplant had significantly faster recovery of blood cell production compared to those who received a placebo with the bone marrow transplant.
CIRM-Funded Clinical Trial Aimed at Blocking HIV/AIDS in People Gets the Go Ahead
March 3, 2015 – An innovative therapy using a patient’s own stem cells, modified to resist infection with the AIDS virus, has been given approval by the Food and Drug Administration (FDA) to begin a clinical trial in people. CIRM, California’s stem cell agency, is funding that trial.
J&J Picks the Inaugural Class for Its Bay Area Biotech Incubator
March 3, 2015 – Johnson & Johnson has opened the doors of its new biotech incubator, bringing in its first 10 resident startups and hoping to galvanize the next generation of life sciences innovators.
Bone Therapeutics Accelerates Its ALLOB® Phase I/IIA Delayed-Union Trial
March 2, 2015 – Bone Therapeutics, the bone cell therapy company addressing high unmet medical needs in the field of bone fracture repair and bone fracture prevention, today announces that the Competent Authorities and Central Ethics Committee in the UK have granted Bone Therapeutics authorisation to extend its Phase I/IIA trial for its cell therapy product ALLOB® in the UK, while the first steps have been taken to receive approval for the trial in France. ALLOB® is Bone Therapeutics’ allogeneic, osteoblastic cell therapy product for the treatment of delayed-union fractures.
Sangamo BioSciences Presents New Clinical Data at CROI 2015 From Trial of ZFP Therapeutic® Designed to Provide Functional Control of HIV
February 26, 2015 – Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the presentation of new clinical data from its Phase 1/2 clinical trial (SB-728-1101). The study is designed to evaluate SB-728-T, a ZFP Therapeutic® generated by ZFN-mediated genome editing of T-cells to knockout the CCR5 gene, which encodes a critical co-receptor for HIV infection. SB-728-T is being developed as a potential ‘functional cure’ for HIV/AIDS.
Cardio3 BioSciences to Raise Capital Via a Private Placement of New Shares
February 26, 2015 – Cardio3 BioSciences (Euronext Brussels and Paris: CARD), a leader in the discovery and development of cell therapies, announces today the launch of a private placement of new ordinary shares to institutional investors. Cardio3 BioSciences intends to raise up to a maximum of 713,380 new shares (10% of the current share capital).
New Director Joins Regeneus Board of Directors
February 23, 2015 – Regenerative medicine company, Regeneus Ltd (ASX: RGS) is pleased to announce the appointment of Dr Glen Richards as an independent non-executive director of Regeneus with effect from April.
TiGenix’s Phase III Trial Design for Cx601 Endorsed by President-Elect of ECCO
February 23, 2015 – TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic expanded adipose-derived stem cells in inflammatory and autoimmune diseases, announced today that Dr Julian Panés, a leading clinical specialist in inflammatory bowel disease, endorsed the design of the Company’s Phase III trial of Cx601 for the treatment of complex perianal fistulas in patients with Crohn’s disease during his presentation last week at the 10th Annual Congress of the European Crohn’s and Colitis Organisation (ECCO) held in Barcelona, Spain.
TiGenix and Lonza Sign Agreement for the Manufacture of Stem Cell-Based Treatment of Complex Perianal Fistulas in Crohn’s Disease
February 12, 2015 – Lonza, a global leader in biological and cell therapy manufacturing and TiGenix, an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from allogeneic expanded adipose-derived stem cells (eASCs) in inflammatory and autoimmune diseases, announced today an agreement for the supply of TiGenix’s eASC product, Cx601.
BrainStorm Receives Notice of Allowance for its NurOwn™ Technology Platform from Israel’s Patent Office
February 9, 2015 – BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has received a Notice of Allowance from Israel’s Patent Office for its patent application titled “Isolated Population of Cells, Methods of Generating Same, and Uses Thereof in the Treatment of CNS Diseases.” This patent is held jointly with Ramot, Tel Aviv University’s technology transfer company.
Sangamo BioSciences Announces FDA Acceptance of IND to Initiate Clinical Trial of its Novel ZFP Therapeutic® for Beta-Thalassemia
February 4, 2015 – Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced today that an Investigational New Drug (IND) application for the company’s SB-BCLmR-HSPC genome editing approach, which is designed to provide a one-time lasting therapy for beta-thalassemia, has been accepted by the U.S. Food and Drug Administration (FDA) and is now active.
BrainStorm Announces Positive DSMB Recommendation in Ongoing Phase 2 Trial with NurOwn™ in ALS
February 3, 2015 – BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that the Data and Safety Monitoring Board (DSMB) met to conduct its first safety review of the randomized, double-blind, placebo-controlled phase 2 clinical trial of NurOwn™ in amyotrophic lateral sclerosis (ALS) that BrainStorm is conducting at three academic medical centers in the U.S.
BrainStorm Announces Exceptional Preclinical Results of NurOwn™ in Mouse Autism Model
January 26, 2015 – BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced positive results from preclinical studies of NurOwn™ in the BTBR mouse model of autism. NurOwn™ cells are mesenchymal stem cells (MSCs) that have been induced, under BrainStorm’s proprietary methods, to secrete a variety of neurotrophic factors. The BTBR mouse exhibits several stereotypical behavioral characteristics that resemble behaviors seen in autism spectrum disorders, including repetitive behaviors, altered social interactions, cognitive rigidity and impaired adaption to environment.
European Patent Office Issues Key Patent to TiGenix for Expanded Adipose-derived Stem Cell Compositions
January 22, 2015 – TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic expanded adipose-derived stem cells in inflammatory and autoimmune diseases, announced today that the European Patent Office (EPO) has issued European Patent EP2292736 relating to an adipose-derived stem cell composition. The patent is entitled “Identification and isolation of multipotent cells from nonosteochondral mesenchymal tissue”.
NeoStem Receives Drug Manufacture License for Irvine Facility
January 20, 2015 – NeoStem, Inc. (NASDAQ:NBS) a leader in the development and manufacturing of cell therapy products and regenerative medicine, announced today that the State of California’s Department of Public Health, Food and Drug Branch has completed its review of NeoStem’s manufacturing and control processes at its Irvine, California cGMP facility for the production of eltrapuldencel-T (also known as NBS20) and has issued NeoStem a manufacturing license permitting NeoStem to manufacture drugs from this facility, including the manufacture of eltrapuldencel-T for clinical trial use. Eltrapuldencel-T is the Company’s patient-specific targeted cancer immunotherapy under investigation for the treatment of Stage IV or recurrent Stage III metastatic melanoma.
Bone Therapeutics Demonstrates Efficacy in First Patient Cohort in ALLOB® Phase I/IIA Delayed-Union Trial
January 19, 2015 – Bone Therapeutics, the bone cell therapy company addressing high unmet medical needs in the field of bone fracture repair and fracture prevention, today announces positive efficacy results for the first cohort of four patients enrolled in the Phase I/IIA delayed-union trial with its allogeneic bone-forming cell product ALLOB®. Results from the initial four patients showed that all four ALLOB®-treated patients met the primary endpoints of the study and three patients have completely healed.
Bone Therapeutics Announces Intention to Launch an Initial Public Offering on Euronext Brussels and Euronext Paris
January 16, 2015 – Bone Therapeutics, the bone cell therapy company addressing high unmet medical needs in the field of bone fracture repair and bone fracture prevention, announces today its intention to raise new funds through an Initial Public Offering on Euronext Brussels and Euronext Paris.
Capricor Therapeutics Initiates the DYNAMIC Clinical Trial for the Treatment of Advanced Heart Failure
January 12, 2015 – Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that the first three patients have been treated in its DYNAMIC clinical trial. The trial is being conducted by Dr. Raj Makkar and his colleagues at Cedars-Sinai Heart Institute in Los Angeles. The Phase I DYNAMIC trial, also known as the “Dilated cardiomYopathy iNtervention with Allogeneic MyocardIally-regenerative Cells” trial, will evaluate CDCs (CAP-1002) in patients with advanced heart failure. The Phase I trial is being funded in part through a grant of approximately $3 million from the National Institutes of Health (NIH).
MiMedx Announces Over 30 National Account Contracts
January 12, 2015 – MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that the status of the Company’s National Account contracts with Group Purchasing Organizations (“GPOs”) and Integrated Delivery Networks (“IDNs”) represent in excess of 4,000 U.S hospitals under contract for MiMedx allografts.
Capricor Therapeutics Announces $10 Million Private Placement of Common Stock
January 12, 2015 – Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that it has signed definitive agreements for the sale of approximately $10.0 million of the Company’s common stock to select investors at a price of $3.52 per share. The placement agents for the financing were H.C. Wainwright & Co., LLC and SC&H Capital.
NeoStem and Invetech Announce Agreement to Develop Closed Processing System for Cell Therapy Manufacturing
January 12, 2015 – NeoStem, Inc. (Nasdaq:NBS), a leader in the development and manufacturing of cell therapy products and regenerative medicine, and Invetech Pty Ltd (“Invetech”), a global leader in instrument development, custom automation and contract manufacturing, today announced an agreement for the development of a new closed processing system (the “System”) for cell therapy manufacturing. Under the agreement, Invetech will provide system design and engineering development and NeoStem will develop applications for performing closed cell processing manipulations such as separation. The agreement envisions NeoStem as the commercial supplier of the System which would constitute its first branded entry into the cell therapy tools market.
JDRF Honors Current and Former ViaCyte Team with Top Scientific Excellence Award
January 12, 2015 – ViaCyte and JDRF announced today that the current and former ViaCyte team are being recognized by JDRF for their pioneering work in developing the VC-01TM product candidate, an innovative treatment currently in a Phase 1/2 clinical trial for type 1 diabetes (T1D). Representing the ViaCyte team, Paul K. Laikind, PhD, President and CEO of ViaCyte, Kevin A. D’Amour, PhD, and Emmanuel E. (Ed) Baetge, PhD, the current and former Chief Scientific Officers of the Company, respectively, will accept the David Rumbough Award for Scientific Excellence at the JDRF International Board Retreat Dinner on January 14th in Los Angeles.
Pluristem Issues Letter to Shareholders
January 12, 2015 – Pluristem Therapeutics Inc. (NasdaqCM, TASE: PSTI), a leading developer of placenta-based cell therapy products, today issued a Letter to Shareholders from its chairmen and CEO, Zami Aberman. Pluristem had a dynamic and exciting 2014. We reported outstanding results in a Phase 2 trial in muscle injury, continued recruitment for two ongoing clinical studies in intermittent claudication and pulmonary arterial hypertension, and laid the groundwork for additional potential clinical studies in several strategically chosen indications.
MiMedx Exceeds Fourth Quarter And Full Year 2014 Revenue Forecasts
January 12, 2015 – MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today its record results for the fourth quarter and full year 2014, and reaffirmed its previous guidance for 2015.
Argos Therapeutics Provides Update on Clinical Research for Investigational Fully Personalized Immunotherapy for the Treatment of HIV
January 9, 2015 – Argos Therapeutics Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on the Arcelis® technology platform, today provided an update on its clinical research program for AGS-004, the company’s investigational fully personalized immunotherapy for the treatment of HIV.
Avalanche Biotechnologies Prices Public Offering of $141.6 Million of Common Stock
January 8, 2015 – Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases, today announced the pricing of its public offering of 2,399,457 shares of its common stock at a public offering price of $59.00 per share, before underwriting discounts, commissions and estimated expenses.
BrainStorm Enters Into Warrant Exercise Agreement for Approximately $13 Million in Proceeds
January 8, 2015 – BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced it has entered into a Warrant Exercise Agreement with certain holders of warrants issued in the June 13, 2014 private placement. These holders have agreed to exercise their warrants in full (for a total of approximately 2.5 million shares of common stock) at an exercise price of $5.22 per share, a 4% premium to the closing price of $5.03, which will generate gross cash proceeds of approximately $13 million.
Sangamo BioSciences Announces In-Licensing Of mRNA Delivery Technology And Expansion Of Therapeutic Pipeline Opportunities For Sangamo’s In Vivo ZFN Genome-Editing Platform
January 8, 2015 – Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced that the company has in-licensed nanoparticle technology to enable systemic messenger RNA (mRNA) delivery of Sangamo’s proprietary zinc finger nucleases (ZFNs). mRNA delivery of ZFNs is being used in the development of the next generation of Sangamo’s ZFP Therapeutics®.
Cardio3 BioSciences Appoints Vincent Brichard as Vice President, Immuno-oncology
January 8, 2015 – Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a leader in the discovery and development of regenerative, protective and reconstructive therapies, announces today the appointment of Dr. Vincent Brichard as Vice President immuno-oncology. In this role, Dr. Brichard will lead the newly acquired immuno-oncology technology platform of Cardio3 BioSciences.
ViaCyte Receives Clearance from Health Canada for Diabetes Clinical Trial
January 8, 2015 – ViaCyte, Inc., a privately-held regenerative medicine company with the first stem cell-derived islet replacement therapy for the treatment of diabetes in clinical trials, has received a No Objection Letter from Health Canada providing clearance to proceed with sites in Canada for the Company’s Phase 1/2 clinical trial of its VC-01TM product candidate. The VC-01 product candidate is currently being evaluated in patients with type 1 diabetes who have minimal to no insulin-producing beta cell function. The location and enrollment start date of the first Canadian clinical trial site have not yet been disclosed.
BrainStorm Announces Receipt of Approximately $3.1 Million from Warrant Exercises
January 7, 2015 – BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that since January 2, 2015 it has received approximately $3.1 million from the exercise of warrants for approximately 700 thousand shares, which were issued in a June 2012 private placement.
Cardio3 BioSciences Enters Immuno-oncology Space with Acquisition of OnCyte CAR T-Cell Portfolio From Celdara Medical
January 6, 2015 – Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a leader in the discovery and development of cell therapies, today announced the acquisition of OnCyte, the oncology division of privately-held U.S. biotechnology company Celdara Medical, and its portfolio of immuno-oncology product candidates. The acquisition marks Cardio3 Biosciences’ entry into the rapidly growing and very promising field of immuno-oncology, positioning the Company at the forefront of the CAR T-Cell space and represents a significant step towards the Company’s strategic objective of developing into a world leader in cell therapy.
Argos Therapeutics and Saint-Gobain Announce Agreement for Production of Disposables Used in Automated Manufacturing of Fully Personalized Immunotherapies
January 6, 2015 – Argos Therapeutics Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on the Arcelis® technology platform, today announced a collaboration with Saint-Gobain’s Performance Plastics division, a leader in high-performance components and solutions using engineered polymers. Under the terms of the agreement, Saint-Gobain will partner with Argos to design, integrate and scale production of a range of disposables for use in the automated manufacturing of Argos’ lead product candidate, AGS-003, currently being tested in a Phase III clinical trial for the treatment of metastatic renal cell carcinoma (mRCC).
Pluristem Granted Patent for Foundational Cell Harvesting Technology in South Africa
January 6, 2015 – Pluristem Therapeutics Inc. (NasdaqCM, TASE: PSTI), a leading developer of placenta-based cell therapy products, announced today that it has been issued Patent No. 2013/07160, titled “Methods and Systems for Harvesting Adherent Stromal Cells”, in South Africa. This patent addresses Pluristem’s methods for using vibration to harvest cells grown on three-dimensional scaffolds, the harvested cells themselves, and devices developed for this process.
MiMedx Announces $10 Million Increase to Stock Repurchase Program
January 6, 2015 – MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today its Board of Directors increased the Company’s authorization for its share repurchase plan from $10,000,000 to $20,000,000. The $20,000,000 authorization announced today amends the $10,000,000 authorization approved in May 2014.
Bone Therapeutics Expands Product Portfolio with New Research into Innovative Combined Cell-Matrix Product
January 5, 2015 – Bone Therapeutics, the regenerative therapy company addressing unmet medical needs in the fields of fracture repair and bone fracture prevention, today announces that it has begun a new research project to investigate novel combined osteoblastic cell-matrix products for the treatment of large bone defects. The government of the Walloon Region has granted the Company €1 million of non-dilutive funding, in the form of recoverable cash advances, to finance this project.
BrainStorm Announces Final Analysis of Phase 2a ALS Study Showing Nearly All Subjects Experienced Clinical Benefit from NurOwn™
January 5, 2015 – BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced positive final results from its phase 2a clinical trial of NurOwn™ in amyotrophic lateral sclerosis (ALS) patients, which enrolled 14 subjects at Hadassah Medical Center in Jerusalem.
TxCell and Ferring Collaboration with Lead Product Ovasave® to Receive Additional Development Expertise from Trizell
January 2, 2015 – TxCell SA (FR0010127662 – TXCL), a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today a further enhancement to the development of its lead product Ovasave® for the treatment of Inflammatory Bowel Diseases (IBD), including Crohn’s disease and ulcerative colitis. The collaboration, option, development and license agreement between TxCell and Ferring International Center SA (Ferring) has been assigned to Trizell Holding SA (Trizell), an affiliate member of the Dr Frederik Paulsen Foundation.
Osiris Announces a Strategic Partnership with Stryker for Marketing Osiris’ Viable Bone Matrix
December 22, 2014 – Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announced today that it has entered into an exclusive, worldwide partnership with Stryker Corporation (NYSE:SYK) for the commercialization and development of Osiris’ viable bone matrix tissue form. Stryker is a global leader in medical technology whose products and services are available in over 100 countries around the world.
Voyager Therapeutics and MassBiologics Announce Strategic Collaboration for Viral Vector Manufacturing
December 11, 2014 – Voyager Therapeutics, a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS), today announced it has entered into a strategic collaboration with MassBiologics of the University of Massachusetts Medical School (UMMS). Through the collaboration, MassBiologics and Voyager Therapeutics will establish scalable processes for manufacturing recombinant adeno-associated viral (rAAV) vector products using current good manufacturing practices (cGMP).
Histogenics Corporation Announces Pricing of Initial Public Offering
December 2, 2014 – Histogenics Corporation (Histogenics), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced the pricing of its underwritten initial public offering of 5,909,091 shares of its common stock at a price to the public of $11.00 per share. The shares are expected to begin trading on the NASDAQ Global Market under the ticker symbol “HSGX” on December 3, 2014.